Finally, in the Ramucirumab Mesothelioma clinical trial (RAMES) [30], mutation of the BAP1 gene was associated with a prolonged median progression-free survival (mPFS) in those patients treated with platinum/pemetrexed regimens (p = 0.04) (Table 1). Here, BAP1 is linked to mesothelioma.